In vivo studies in a non-human primate (NHP) SIV infection model have shown that administration of a monoclonal antibody against the α4β7 complex can be protective from HIV infection during mucosal challenge, and decrease the loss of CD4+ T cells in GALT [7]. This evidence concerns the gene CD4 and HIV infectious disease.